Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis

Stephanie D. Davis*, Felix Ratjen, Lyndia C. Brumback, Robin C. Johnson, Amy G. Filbrun, Gwendolyn S. Kerby, Howard B. Panitch, Scott H. Donaldson, Margaret Rosenfeld, Stephanie Davis, Albert Faro, Amy Filbrun, Peter Hiatt, Gwendolyn Kerby, Karen McCoy, Karen McDowell, James Acton, Carlos Milla, Howard Panitch, Adrienne PrestridgePeggy Radford, Clement Ren, Jack Sharp

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


Background: The Infant Study of Inhaled Saline (ISIS) in CF was the first multicenter clinical trial to utilize infant pulmonary function tests (iPFTs) as an endpoint. Methods: Secondary analysis of ISIS data was conducted in order to assess feasibility of iPFT measures and their associations with respiratory symptoms. Standard deviations were calculated to aid in power calculations for future clinical trials. Results: Seventy-three participants enrolled, 70 returned for the final visit; 62 (89%) and 45 (64%) had acceptable paired functional residual capacity (FRC) and raised volume measurements, respectively. Mean baseline FEV0.5, FEF75 and FRC z-scores were 0.3 (SD: 1.2), -0.2 (SD: 2.0), and 1.8 (SD: 2.0). Conclusions: iPFTs are not appropriate primary endpoints for multicenter clinical trials due to challenges of obtaining acceptable data and near-normal average raised volume measurements. Raised volume measures have potential to serve as secondary endpoints in future clinical CF trials.

Original languageEnglish (US)
Pages (from-to)386-391
Number of pages6
JournalJournal of Cystic Fibrosis
Issue number3
StatePublished - May 1 2016


  • FEV
  • Forced expiratory flow rates
  • Pulmonary function tests

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pediatrics, Perinatology, and Child Health


Dive into the research topics of 'Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis'. Together they form a unique fingerprint.

Cite this